NBIO Stock Chart & Stats
$0.08
<$0.01(20.00%)
At close: 4:00 PM EDT
$0.08
<$0.01(20.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.13
Previous CloseN/A
Volume11.00K
Average Volume (3M)66.98K
Market Cap
$51.66K
Enterprise Value-$197.96K
Total Cash (Recent Filing)$47.39K
Total Debt (Recent Filing)$59.00K
Price to Earnings (P/E)―
Beta55.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding172,842,670
10 Day Avg. Volume104,925
30 Day Avg. Volume66,979
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-109.22
Price to Sales (P/S)0.00
P/FCF Ratio-23.64
Enterprise Value/Market Cap-3.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.67
Enterprise Value/Ebitda0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nascent Biotech News
NBIO FAQ
What was Nascent Biotech Inc.’s price range in the past 12 months?
Nascent Biotech Inc. lowest stock price was <$0.01 and its highest was $0.13 in the past 12 months.
What is Nascent Biotech Inc.’s market cap?
Nascent Biotech Inc.’s market cap is $51.66K.
When is Nascent Biotech Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nascent Biotech Inc.’s earnings last quarter?
Currently, no data Available
Is Nascent Biotech Inc. overvalued?
According to Wall Street analysts Nascent Biotech Inc.’s price is currently Overvalued.
Does Nascent Biotech Inc. pay dividends?
Nascent Biotech Inc. does not currently pay dividends.
What is Nascent Biotech Inc.’s EPS estimate?
Nascent Biotech Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nascent Biotech Inc. have?
Nascent Biotech Inc. has 172,842,670 shares outstanding.
What happened to Nascent Biotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nascent Biotech Inc.?
Currently, no hedge funds are holding shares in NBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nascent Biotech Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Aditxt
―
GRI Bio
―
CERo Therapeutics Holdings
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors